Andrea Dória Batista

Andrea Dória Batista

Auto-generated profile, based on publicly available information

Andrea Dória Batista

Universidade Federal de Pernambuco

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
ISIsabella Patrícia Lima Silva
Isabella Patrícia Lima Silva
ABAndrea Dória Batista
Andrea Dória Batista
ELEdmundo Pessoa Lopes
Edmundo Pessoa Lopes
NFNorma Arteiro Filgueira
Norma Arteiro Filgueira
BCBernardo Times de Carvalho
Bernardo Times de Carvalho
HLHeloisa Ramos Lacerda
Heloisa Ramos Lacerda
The efficacy of direct-acting antivirals (DAAs) in the treatment of chronic hepatitis C (CHC) in liver transplant recipients is poorly understood, and several factors, including immunosuppression, drug interactions, elevated viraemia, and intolerance to ribavirin (RBV), can reduce cure rates. We conducted a real-life study on liver transplant recipients with CHC treated with a combination of sofosbuvir (SOF) and daclatasvir (DCV) or simeprevir (SIM), with or without RBV, followed-up for 12 to 24 weeks. The treatment effectiveness was assessed by determining the sustained virological response (SVR) rates at 12 or 24 weeks after the treatment cessation. Eighty-four patients were evaluated, with a mean age of 63.4 ± 7.4 years, HCV genotype 1 being the most prevalent (63.1%). Nineteen patients (22.7%) had mild fibrosis (METAVIR < F2) and 41 (48.8%) significant fibrosis (METAVIR ≥ F2). The average time between liver transplantation and the start of treatment was 4 years (2.1-6.6 years). The SOF + DCV regimen was used in 58 patients (69%). RBV in combination with DAAs was used in seven patients (8.3%). SVR was achieved in 82 patients (97.6%), and few relevant adverse events could be attributed to DAA therapy, including a patient who stopped treatment due to a headache. There was a significant reduction in ALT, AST, GGT and FA levels, or the APRI index after 4 weeks of treatment, which remained until 12/24 weeks post-treatment. DAA treatment of CHC in liver-transplanted patients achieved a high SVR rate and resulted in the normalization of serum levels of liver enzymes.

13 January 2025 in Revista de Epidemiologia e Controle de Infecção
Verified
Journal Article
Open access
PDF file
MVMaria Tereza Estevam Vaz Vaz
Maria Tereza Estevam Vaz Vaz
NFNorma Arteiro Filgueira Filgueira
Norma Arteiro Filgueira Filgueira
PSPaula Carolina Valença Silva
Paula Carolina Valença Silva
ADAlcides da Silva Diniz Diniz
Alcides da Silva Diniz Diniz
LALílian Rose Maia Gomes de Araújo Araújo
Lílian Rose Maia Gomes de Araújo Araújo
ELEdmundo Pessoa Lopes
Edmundo Pessoa Lopes
Background and Objectives: Hepatitis C virus (HCV) infection is a relevant public health problem due to its prevalence and possible progression to cirrhosis and hepatocellular carcinoma. Although the use of direct-acting antivirals has decreased the incidence in recent years, identifying those infected remains a challenge for the elimination of HCV by 2030. The objective of this study was to estimate the prevalence of HCV antibody (anti-HCV), and describe the sociodemographic and behavioral risk factors associated with HCV infection in individuals in a small town in the Brazilian semi-arid region. Methods: Following a non-random sampling procedure, a cross-sectional study of 800 individuals in the waiting rooms of Basic Health Units (BHU) was conducted. After formal consent, a rapid screen test for anti-HCV (Immunochromatography)was carried out, and a questionnaire was applied to collect sociodemographic, clinical and risk behavior data. Results: Five tests were positive (0.62%; 95%CI 0.2 – 1.4%), four women and one man. All were over 60 years old (mean age of 69.4) and some risk behaviors in the past, use of glass syringes, surgery, or blood transfusion, were statistically associated with HCV exposure. Conclusion: In this study, a low prevalence of anti-HCV was observed, close to that estimated in recent studies. The antibody was more frequently positive in older individuals, aged over 60 years, who reported risky past behavior. Greater attention should be given to these individuals.

1 January 2000 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
FSF. Serejo
F. Serejo
ACA. Costa
A. Costa
FRF. Ramalho
F. Ramalho
ABA. Batista
A. Batista
MMM.C. Moura
M.C. Moura

15 September 2026 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
RPRafaella Italiano Peixoto
Rafaella Italiano Peixoto
ABAndrea Dória Batista
Andrea Dória Batista
AOArmando Ykaro Soares de Oliveira
Armando Ykaro Soares de Oliveira
ADAna Lúcia Coutinho Domingues
Ana Lúcia Coutinho Domingues
PAPaulo Sergio Ramos Araujo
Paulo Sergio Ramos Araujo